Quote:
5. Ivermectin
Ivermectin (IVM) is a broad spectrum anti-parasitic agent
that has been shown to have anti-viral activity against a range
of viruses including recently, SARS-CoV-2 (Heidary and Gharebaghi, 2020). This drug is well tolerated, has a high therapeutic
index and proven safety profile with over 3.7 billion treatments,
and has been used alone or combined with either doxycycline or
azithromycin in early clinical studies of patients with COVID-19
(Rahman et al., 2020). There are a number of randomized and
prospective studies and all have shown efficacy in clinical outcomes at the time of this report (Alam et al., 2020; Chowdhury
et al., 2020; Gorial et al., 2020; Khan et al., 2020; Nunez et al.,
2020). Hence, it is reasonable in patients where HCQ cannot be
used and favipiravir is not available, that IVM (200-600 mcg/kg
[6-36 mg] single oral dose given daily or every other day for 2-
3 administrations) could be the base of SMDT intended to reduce
viral replication early in the course of COVID-19. However, uncertainty remains at this time concerning optimal dosing and schedule
(Schmith et al., 2020). In the ICON study, IVM use in the hospital was associated with a 48% relative risk reduction in COVID-19
mortality (Rajter et al., 2020). Currently, there are 36 randomized
clinical trials of ivermectin alone or in combination for ambulatory
and hospitalized patients listed on clinicaltrials.gov.
C'mon Rip, I am sure you know how to use Ctrl-F.